natgillin/translations-raw huggingface dataset:
Adverse reactions reported in subjects who received Naltrexone/Bupropion, Naltrexone and Bupropion
Neželeni učinki, o katerih so poročali pri preiskovancih, ki so prejemali naltrekson/bupropion, naltrekson in bupropion
Adverse reactions reported in the double-blind period of the Phase 3 study
Neželeni učinki, o katerih so poročali v dvojno slepem obdobju študije 3. faze
Adverse reactions reported in the literature are pruritus and increased serum transaminases in one or two children treated with high doses of cholic acid; however these adverse reactions disappeared with a reduced dosage.
Neželena učinka, o katerih so poročali v literaturi, sta pruritus in povišana raven transaminaz v serumu pri enem ali dveh otrocih, zdravljenih z velikimi odmerki holne kisline, vendar sta ta neželena učinka izzvenela z zmanjšanjem odmerka.
Adverse reactions reported in the pooled dataset for patients treated with nivolumab monotherapy (n=1728) and for patients treated with nivolumab in combination with ipilimumab (n=448) are presented in Table 2.
Neželeni učinki so v preglednici 2 navedeni na osnovi zbranih podatkov pri bolnikih, ki so se zdravili z nivolumabom v monoterapiji (n = 1.728) in bolnikih, ki so se zdravili z nivolumabom v kombinaciji z ipilimumabom (n=448).
Adverse reactions reported in ≥ 1% of patients with soft tissue sarcoma in clinical trials.
Neželeni učinki, o katerih so poročali pri ≥ 1 % bolnikov s sarkomom mehkega tkiva v kliničnih preskušanjih
Adverse reactions reported in ≥ 5% of patients in clinical trial ET743-OVA-301
Neželeni učinki, o katerih so poročali pri ≥ 5 % bolnikov v kliničnem preskušanju ET743-OVA-301
Adverse reactions reported in ≥ 5% of patients treated with saxagliptin 5 mg and more commonly than in patients treated with placebo or that were reported in ≥ 2% of patients treated with saxagliptin 5 mg and ≥ 1% more frequently compared to placebo are shown in Table 1.
Preglednica 1 prikazuje neželene učinke, ki so bili zabeleženi pri ≥ 5 % bolnikov, zdravljenih s 5 mg saksagliptina, in pogosteje kot pri bolnikih, ki so dobivali placebo, ali pri ≥ 2 % bolnikov zdravljenih s 5 mg saksagliptina, in ≥ 1 % pogosteje kot s placebom.
Adverse reactions reported in ≥ 5% of patients treated with saxagliptin 5 mg and more commonly than in patients treated with placebo or that were reported in ≥ 2% of patients treated with saxagliptin 5 mg and ≥ 1% more frequently compared to placebo from the pooled analysis of five studies of glycaemic control, plus an additional active-controlled study of initial combination with metformin are shown in Table 1.
Neželene učinke, ki so bili poročani pri  5% bolnikih, ki so dobivali 5 mg saksagliptina in so bolj pogosti kot pri bolnikih, ki so dobivali placebo, ali tiste, ki so bili poročani pri  2% bolnikih, ki so dobivali 5 mg saksagliptina in so  1 % bolj pogosti v primerjavi s placebom, iz kumulativne analize petih študij urejenosti glikemije ter ene dodatne, z zdravilno učinkovino kontrolirane študije začetne kombinacije z metforminom prikazuje preglednica 1.
Adverse reactions reported when linagliptin and metformin were combined with insulin
Neželeni učinki, o katerih so poročali pri kombinaciji linagliptina in metformina z insulinom
Adverse reactions reported when linagliptin and metformin were combined with sulphonylurea
Neželeni učinki, o katerih so poročali pri kombinaciji linagiptina in metformina s sulfonilsečnino
Adverse reactions reported when linagliptin and metformin were combined with sulphonylurea When linagliptin and metformin were administered in combination with a sulphonylurea, hypoglycaemia was identified as an additional adverse reaction under these conditions.
Neželeni učinki, o katerih so poročali pri kombinaciji linagiptina in metformina s sulfonilsečnino Če so linagliptin in metformin dajali v kombinaciji s sulfonilsečnino, je bila hipoglikemija pod temi pogoji opredeljena kot dodaten neželeni učinek.
Adverse reactions reported with an incidence greater than placebo, during the Lennox-Gastaut syndrome double-blind studies or in the overall rufinamide-exposed population, are listed in the table below by MedDRA preferred term, system organ class and by frequency.
Neželeni učinki z incidenco večjo od placeba, v dvojno slepih študijah Lennox-Gastautovega sindroma ali v celotni populaciji, izpostavljeni rufinamidu, so navedeni v spodnji preglednici po imenih, organskih sistemih in pogostnosti, ki jih predpisuje MedDRA.
Adverse reactions reported with ofatumumab in previously untreated and relapsed or refractory CLL patients, either alone or in combination with an alkylating agent, are listed below by MedDRA body system organ class and by frequency.
Neželeni učinki, opisani z ofatumumabom samim ali v kombinaciji s kakšnim alkilirajočim zdravilom pri predhodno nezdravljenih bolnikih, bolnikih z recidivom ali bolnikih z odporno KLL, so navedeni spodaj po organskih sistemih MedDRA in pogostnosti.
Adverse reactions reported with the fixed dose combination
Neželeni učinki, o katerih so poročali pri fiksni kombinaciji odmerkov
Adverse reactions reported with the fixed dose combination
Neželeni učinki, o katerih so poročali pri uporabi fiksne kombinacije
Adverse reactions reported with the use of hydrochorothiazide alone
Neželeni učinki (neodvisno od zdravila), o katerih so poročali pri uporabi hidroklorotiazida samega
Adverse reactions reported with the use of hydrochorothiazide alone
Neželeni učinki, o katerih so poročali pri uporabi hidroklorotiazida samega
Adverse reactions reported with the use of irbesartan alone
Neželeni učinki, o katerih so poročali pri uporabi irbesartana samega
Adverse reactions seen during the course of this study included vomiting, diarrhoea, skin lesions, salivation, tremors, decreased activity, coughing and vocalization.
Med neželenimi učinki, opaženimi med to študijo, so bili bruhanje, diareja, kožne lezije, slinjenje , tremor, zmanjšana aktivnost, kašelj in vokalizacija.
Adverse reactions seen with desloratadine
Neželeni učinki opaženi pri zdravilu Desloratadin Actavis
Adverse reactions seen with olanzapine
Neželeni učinki, ki so jih opazili pri olanzapinu
Adverse reactions such as chills, headache, dizziness, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally in connection with intravenous administration of human immunoglobulin including Privigen.
Občasno se lahko pojavijo neželeni učinki, kot so mrzlica, glavobol, omotica, povečana telesna temperatura, bruhanje, alergijske reakcije, navzea, bolečine v sklepih, nizek krvni tlak in zmerna bolečina v križu v povezavi z intravenskim dajanjem humanih imunoglobulinov, vključno z zdravilom Privigen.
Adverse reactions such as chills, headache, dizziness, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally.
Občasno se lahko pojavijo neželeni učinki kot so mrzlica, glavobol, omotica, povišana telesna temperatura, bruhanje, alergijske reakcije, navzea, artralgija, nizek krvni tlak ter zmerna bolečina v ledvenem delu hrbta.
Adverse reactions such as chills, headache, dizziness, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally.
Občasno se lahko pojavijo neželeni učinki, kot so mrzlica, glavobol, omotica, povišana telesna temperatura, bruhanje, alergijske reakcije, navzea, artralgija, nizek krvni tlak ter zmerna bolečina v ledvenem delu hrbta.
Adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia (joint pain), low blood pressure and moderate low back pain may occur occasionally.
Občasno se lahko pojavijo neželeni učinki, kot so mrzlica, glavobol, povišana telesna temperatura, bruhanje, alergijske reakcije, slabost, artralgija (bolečine v sklepih), nizek krvni tlak ter zmerna do šibka bolečina v hrbtu.
Adverse reactions such as dizziness, somnolence, diplopia and blurred vision were reported in controlled clinical studies, particularly during titration (see section 4.8).
V kliničnih študijah so bili, zlasti med titriranjem, opisani neželeni učinki, npr. omotica, zaspanost, diplopija in zamegljen vid (glejte poglavje 4.8).
Adverse reactions such as fatigue and weakness have been associated with cabozantinib.
Z uporabo kabozantiniba so povezani neželeni učinki, kot so utrujenost in šibkost.
Adverse reactions such as: vomiting, diarrhoea, lack of energy, decreased appetite and itching were uncommonly observed.
Redko so bili opaženi neželeni učinki kot so: bruhanje, driska, pomanjkanje energije, zmanjšan apetit in srbečica.
Adverse reactions such as: vomiting, diarrhoea, lethargy, anorexia, and pruritus were uncommonly observed.
Redko so bili opaženi neželeni učinki kot so: bruhanje, driska, letargija, neješčnost in srbečica.
Adverse reactions that have been observed with bazedoxifene monotherapy
Neželeni učinki, ki so jih opazili pri monoterapiji z bazedoksifenom.
Adverse reactions that have been observed with CE monotherapy
Neželeni učinki, ki so jih opazili pri monoterapiji s CE.
Adverse reactions that may suggest increase in prolactin levels (e.g. amenorrhoea, galactorrhoea, menstrual disturbances, gynaecomastia) were reported overall in < 1% of subjects.
O neželenih pojavih, ki bi lahko bili povezani s prolaktinom (amenoreja, galaktoreja, motnje menstruacije, ginekomastija) pa so poročali pri skupaj < 1% preiskovancev.
Adverse reactions that most commonly led to dose reductions (in ≥5% of patients) were hypertension, proteinuria, diarrhoea, fatigue, PPE, weight decreased, and decreased appetite.
Neželeni učinki, ki so najpogosteje povzročili zmanjšanje odmerka (pri ≥5 % bolnikov), so bili hipertenzija, proteinurija, driska, utrujenost, PPE, hujšanje in zmanjšan apetit.
Adverse reactions that occurred during clinical studies or that were spontaneously reported from post- marketing experience are listed by frequency in the table below.
Neželeni učinki ki so se pojavili med kliničnimi študijami in ki so bili spontano poročani med izkušnjami v obdobju trženja so po pogostnosti našteti v spodnji preglednici.
Adverse reactions that occurred with clopidogrel alone, with ASA alone or with clopidogrel in combination with ASA either during clinical studies or that were spontaneously reported are presented in the table below.
Neželeni učinki, zabeleženi samo s klopidegrelom, samo z ASA ali s klopidogrelom v kombinaciji z ASA v kliničnih študijah ali opisani spontano, so našteti v spodnji tabeli.
Adverse reactions that were most frequently reported to lead to discontinuation were dizziness, somnolence, fatigue and confusional state.
Neželeni učinki, ki so najpogosteje povzročili prenehanje zdravljenja, so bili omotica, somnolentnost, utrujenost in stanje zmedenosti.
Adverse reactions that were reported for the 32 patients treated with 0.5 mg/kg idursulfase weekly in the TKT024 phase II/III 52-week placebo-controlled study were almost all mild to moderate in severity.
Skoraj vsi neželeni učinki, o katerih so poročali pri 32 bolnikih, ki so jih zdravili z 0,5 mg/kg idursulfaze na teden v 52-tedenski, s placebom nadzorovani študiji TKT024 II./III. faze, so bili blagi do zmerni.
Adverse reactions that were reported in post-marketing experience are listed below (Table 2), by system organ class and frequency as follows:
Neželeni učinki, o katerih so poročali v obdobju trženja, so našteti spodaj (preglednica 2), po organskih sistemih ter pogostnosti pojavljanja:
Adverse reactions to cobicistat-boosted atazanavir during 144 weeks of clinical trial experience from study GS-US-216-0114 are listed in Table 3, below, by body system organ class and frequency.
Neželeni učinki za atazanavir, okrepljen s kobicistatom, pridobljeni iz izkušenj 144-tedenske klinične študije GS-US-216-0114, so našteti v spodnji preglednici 3 po organskih sistemih in pogostnosti.
Adverse reactions to elvitegravir from clinical study experience are listed in Table 3 below, by body system organ class and frequency.
Neželeni učinki elvitegravirja iz izkušenj v klinični študiji so našteti v spodnji preglednici 3 po organskih sistemih in pogostnosti.
Adverse reactions to OPTISON are rare and usually of a non-serious nature.
Neželeni učinki kontrastegan sredstva OPTISON so redki in običajno niso resni.
Adverse reactions to orlistat are largely gastrointestinal in nature.
Neželeni učinki pri jemanju orlistata so večinoma povezani s prebavili.
Adverse reactions to Stribild from Phase 3 clinical studies GS-US-236-0102 and GS-US-236-0103 and adverse reactions to treatment with emtricitabine and tenofovir disoproxil fumarate from clinical studies and post-marketing experience, when used with other antiretrovirals, are listed in Table 2, below, by body system organ class and highest frequency observed.
Spodaj v preglednici 2 so po organskih sistemih in največji opazovani pogostnosti navedeni neželeni učinki zdravila Stribild iz kliničnih študij faze 3, GS-US-236-0102 in GS-US-236-0103 in neželeni učinki zdravljenja z emtricitabinom in dizoproksiltenofovirijevim fumaratom iz kliničnih študij in izkušenj v obdobju trženja zdravila, pri uporabi z drugimi protiretrovirusnimi zdravili.
Adverse reactions were categorized as very common (( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1,000 to < 1/100), rare ( 1/10,000 to < 1/1,000), very rare (< 1/10,000) or not known (cannot be estimated from available data).
Neželeni učinki so bili razvrščeni kot zelo pogosti ( 1/10), pogosti ( 1/100 do < 1/10), občasni ( 1/1.000 do < 1/100), redki ( 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) ali neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions were defined as events occurring in at least 1% of patients on bosentan and at a frequency at least 0.5% more than on placebo.
Neželeni učinki so bili opredeljeni kot dogodki, ki so se pojavili pri vsaj 1 % bolnikov na bosentanu in z vsaj 0,5% večjo pogostnostjo kot pri bolnikih na placebu.
Adverse reactions were determined based on pooled data from seven randomised, double-blind, placebo-controlled studies of Aranesp with a total of 2112 patients (Aranesp 1200, placebo 912).
Neželene učinke so ugotavljali na podlagi kumulativnih podatkov sedmih randomiziranih, dvojno slepih, s placebom kontroliranih študij zdravila Aranesp pri skupaj 2112 bolnikih (zdravilo Aranesp 1200, placebo 912).
Adverse reactions were determined based on pooled data from seven randomised, double-blind, placebo-controlled studies of Nespo with a total of 2112 patients (Nespo 1200, placebo 912).
Neželene učinke so ugotavljali na podlagi kumulativnih podatkov sedmih randomiziranih, dvojno slepih, s placebom kontroliranih študij Nespoa pri skupaj 2112 bolnikih (Nespo 1200, placebo 912).
Adverse reactions were generally consistent with those seen in previous studies of the individual components.
Neželeni učinki so bili načeloma konsistentni s tistimi iz predhodnih študij posameznih zdravilnih učinkovin.
Adverse reactions were mild, transient, and consistent with the most frequently reported adverse reactions for pirfenidone.
Neželeni učinki so bili blagi, prehodni in skladni z najpogosteje navedenimi neželenimi učinki pirfenidona.
Adverse reactions were more frequent in females and in patients more than 65 years of age in both the bivalirudin and the heparin-treated comparator groups compared to male or younger patients.
V primerjalnih skupinah, ki so jo zdravili tako z bivaluridinom kot s heparinom, so bili neželeni učinki pogostejši pri ženskah in bolnikih, starejših od 65 let, kot pri moških in mladih bolnikih.
Adverse reactions were rare in dogs treated with difloxacin.
Neželeni učinki pri psih, zdravljenih z difloxacinom, so redki.
Adverse reactions were reported in 93% of Benlysta-treated patients and 92% of placebo-treated patients.
Neželeni učinki so bili opisani pri 93 % bolnikov, zdravljenih z zdravilom Benlysta, in 92 % bolnikov, ki so prejemali placebo.
Adverse reactions were reported with the following frequencies (Very common  1/10; Common
O neželenih učinkih so poročali z naslednjo pogostnostjo (zelo pogosti  1/10; pogosti  1/100 do
Adverse reactions were similar to those seen at lower doses.
Neželeni učinki so bili podobni tistim, opažanim pri nižjih odmerkih.
Adverse reactions were typically mild to moderate and seldom led to discontinuation.
Neželeni učinki so bili praviloma blagi do zmerni in so redko povzročili prenehanje uporabe zdravila.
Adverse reactions with at least 2% difference over placebo are in italics.
Neželeni učinki z najmanj 2 % razliko v primerjavi s placebom so napisane v poševni pisavi.
Adverse reactions with at least 2% difference over placebo are in italics.
Neželeni učinki z najmanj 2% razliko v primerjavi s placebom so napisani v poševni pisavi.
Adverse reactions with at least 2% difference over placebo are marked in italics.
Neželene učinke z najmanj 2 % razliko v primerjavi s placebom so napisane v poševni pisavi.
Adverse reactions with BRINAVESS *
Neželeni učinki z zdravilom BRINAVESS
Adverse reactions with Repatha
Neželeni učinki z zdravilom Repatha
Adverse Reactions – all Grades
Neželeni učinki vseh stopenj
Adverse Reactions – Neurosurgery
Neželeni učinki – nevrokirurški posegi
Adverse Reactions – Vascular Surgery
Neželeni učinki – žilni kirurški posegi
ADVERSE REACTIONS*
NEŽELENI UČINKI
Adverse reactions, considered at least possibly attributable to cinacalcet treatment in the placebo controlled studies and single-arm studies based on best-evidence assessment of causality are listed below using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000).
Neželeni učinki, ki jih je na podlagi ocene najboljših dokazov o vzročnosti vsaj možno pripisati zdravljenju s cinakalcetom iz študij, kontroliranih s placebom, in študij z enim krakom, so navedeni spodaj ob upoštevanju sledečega dogovora: zelo pogosti (� 1/10), pogosti (� 1/100 do < 1/10), občasni (� 1/1.000 do < 1/100), redki (� 1/10.000 do < 1/1.000), zelo redki (< 1/10.000).
Adverse Reactions, Probably or Possibly Related to CellCept, Reported in Patients Treated with CellCept in Renal and Hepatic Clinical Trials when Used in Combination with Ciclosporin and Corticosteroids
Neželeni učinki, verjetno ali možno povezani z zdravilom CellCept, ki so se pojavili pri bolnikih zdravljenih z zdravilom CellCept v kombinaciji s ciklosporinom in kortikosteroidi pri kliničnih preskušanjih bolnikov z ledvičnim ali jetrnim presadkom.
Adverse Reactions, Probably or Possibly Related to CellCept, Reported in Patients Treated with CellCept in Renal, Cardiac and Hepatic Clinical Trials when Used in Combination with Ciclosporin and Corticosteroids
Neželeni učinki, verjetno ali možno povezani z zdravilom CellCept, ki so se pojavili pri bolnikih zdravljenih z zdravilom CellCept v kombinaciji s ciklosporinom in kortikosteroidi pri kliničnih preskušanjih bolnikov z ledvičnim, srčnim ali jetrnim presadkom.
Adverse reactions, probably or possibly related to CellCept, reported in ≥1/10 and in ≥1/100 to
Neželeni učinki, ki so verjetno ali možno povezani z zdravilom CellCept in so se pojavili pri  1/10 in pri  1/100 do
Adverse reactions, probably or possibly related to CellCept, reported in 1/10 and in 1/100 to <1/10 of patients treated with CellCept in the controlled clinical trials of renal (2 g data), cardiac and hepatic transplant patients are listed in the following table.
Neželeni učinki, ki so verjetno ali možno povezani z zdravilom CellCept in so se pojavili pri  1/10 in pri  1/100 do < 1/10 bolnikov, zdravljenih z zdravilom CellCept v nadziranih kliničnih preskušanjih bolnikov z ledvičnim (podatki za 2 g), srčnim ali jetrnim presadkom, so našteti v spodnji preglednici.
Adverse reactions, probably or possibly related to CellCept, reported in 1/10 and in 1/100 to<1/10 of patients treated with CellCept in the controlled clinical trials of renal (2 g data), cardiac and hepatic transplant patients are listed in the following table.
Neželeni učinki, ki so verjetno ali možno povezani z zdravilom CellCept in so se pojavili pri  1/10 in pri  1/100 do < 1/10 bolnikov, zdravljenih z zdravilom CellCept v nadziranih kliničnih preskušanjih bolnikov z ledvičnim (podatki za 2 g), srčnim ali jetrnim presadkom, so našteti v spodnji preglednici.
Adverse reactions, probably or possibly related to mycophenolate mofetil, reported in 1/10 and in
Neželeni učinki, ki so verjetno ali možno povezani z mofetilmikofenolatom in so se pojavili pri 1/10 in pri
Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines, therefore caution should be exercised with the use of zoledronic acid along with driving and operating of machinery.
Neželeni učinki, kot na primer omotica in somnolenca, lahko vplivajo na sposobnost vožnje in upravljanja s stroji, zato je ob uporabi zoledronske kisline potrebna previdnost pri vožnji in upravljanju s stroji.
Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines, therefore caution should be exercised with the use of zoledronic acid along with driving and operating of machinery.
Neželeni učinki, kot na primer vrtoglavost in somnolenca, lahko vplivajo na sposobnost vožnje in upravljanja s stroji, zato je ob uporabi zoledronske kisline potrebna previdnost pri vožnji in upravljanju s stroji.
Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines, therefore caution should be exercised with the use of Zometa along with driving and operating of machinery.
Neželeni učinki, kot na primer vrtoglavost in somnolenca, lahko vplivajo na sposobnost vožnje in upravljanja s stroji, zato je ob uporabi zdravila Zometa potrebna previdnost pri vožnji in upravljanju s stroji.
Adverse reactions, such as dizziness, may affect the ability to drive or use machines, though no studies on this effect with Zoledronic acid Teva Pharma have been performed.
Neželeni učinki, kot je na primer omotičnost, lahko vplivajo na sposobnost vožnje in upravljanja s stroji, vendar študij o takem vplivu zdravila Zoledronska kislina Teva Pharma niso izvedli.
Adverse reactions, such as dizziness, may affect the ability to drive or use machines.
Neželeni učinki, kot je omotičnost, lahko vplivajo na sposobnost vožnje in upravljanja s stroji.
Adverse Reactionsa
Neželeni učinkia
Adversereaction
Neželeni učinek
Advice about the immunogenicity laboratory testing program for detecting these antibodies for following up suspected immune complex-mediated disease, and about the procedure to follow for the collection and shipment of a blood sample to the company’s central laboratory.
Nasvet glede laboratorijskega programa testiranja imunogenosti za odkrivanje teh protiteles za spremljanje morebitnih bolezni, povzročenih z imunskimi kompleksi, in glede postopka, ki ga je treba upoštevati pri zbiranju in odpremi vzorca krvi v osrednji laboratorij podjetja.
Advice about the immunogenicity laboratory testing program for these antibodies provided by the company for following up suspected emergence of neutralising antibodies and information about the procedure to follow for the collection and shipment of a blood sample to the company’s central laboratory.
Nasvet glede laboratorijskega programa testiranja imunogenosti za ta protitelesa, ki ga zagotovi podjetje za spremljanje morebitnega pojava nevtralizirajočih protiteles, in glede postopka, ki ga je treba upoštevati, za zbiranje in odpremo vzorca krvi v osrednji laboratorij podjetja.
Advice for dog owner
Nasvet za lastnika psa
Advice for Dog Owner
Nasvet za lastnika psa:
Advice for Veterinarian
Nasvet za veterinarja:
Advice for Veterinarian:
Nasvet za veterinarja
ADVICE ON CORRECT ADMINISTRATION
NASVETI O PRAVILNI UPORABI ZDRAVILA
ADVICE ON CORRECT ADMINISTRATION Care should be taken to apply the product to intact skin.
NASVET O PRAVILNI UPORABI ZDRAVILA Paziti je treba, da zdravilo nanašate na nepoškodovano kožo.